China's manufacturing activity contracted sharply in December for the third month in a row, according to Purchasing Managers' Index (PMI)
The coutry’s PMI came in at 47 points, down from November's 48 and well below the 50-point mark separating growth from contraction, despite China loosening COVID restrictions at the beginning of the month.
For over two years, China had imposed a zero-COVID strategy with strict quarantines, lockdowns, and mass testing that led to unannounced plant closures, disrupted supply chains, and forced permanent company closures.
China abruptly loosened pandemic restrictions on December 7, but the country is still struggling to recover due to a surge in COVID cases.
NBS senior statistician Zhao Qinghe noted that the pandemic has had a significant impact on business production and demand, staff presence, logistics, and distribution.
The index has not been in positive territory since September, and December's figure was lower than the 47.8 reading predicted by Bloomberg analysts.
For its part, the non-manufacturing PMI -- which includes the services and construction sectors -- also contracted further this month, to 41.6 points from 46.7 in November.


Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
China Car Sales Drop Again as EV Export Growth Surges in April
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 



